NCDN

Across TCGA pan-cancer cohorts, NCDN mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NCDN data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NCDN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NCDN expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where NCDN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.840	0.625	.002	10	view →
HNSC	DFS	Quartile	All	0.823	0.566	.015	9	view →
LSCC	OS	Median	III,IV	0.459	0.864	.014	7	view →
OV	DFS	Median	All	0.847	1.000	.019	4	view →
UCEC	OS	Tertile	All	0.816	0.974	.025	4	view →
GBM	DFS	Quartile	All	0.275	0.528	.026	2	view →
LUAD	OS	Median	II,III,IV	1.000	0.807	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NCDN–PDAC (DFS)

Open the PDAC breakdown →